Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care

Aim Type 2 diabetes (T2D) is a risk factor for metabolic dysfunction-associated fatty liver disease (MAFLD), which is becoming the commonest cause of chronic liver disease worldwide. We estimated MAFLD prevalence among patients with T2D using the hepatic steatosis index (HSI) and validated it agains...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of endocrinological investigation 2021-09, Vol.44 (9), p.1879-1889
Hauptverfasser:	Morieri, M. L., Vitturi, N., Avogaro, A., Targher, G., Fadini, G. P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Age Aged Aged, 80 and over Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - epidemiology Endocrinology Fatty liver Fatty Liver - complications Fatty Liver - epidemiology Fatty Liver - therapy Female Follow-Up Studies Gliclazide - therapeutic use Humans Hypoglycemic Agents - therapeutic use Incretins - therapeutic use Internal Medicine Italy - epidemiology Kidney diseases Liver diseases Male Medicine Medicine & Public Health Metabolic Diseases Middle Aged Nephropathy Original Article Patients Prevalence Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - epidemiology Retrospective Studies Risk factors Steatosis Treatment Outcome Ultrasonic imaging Ultrasonography Ultrasound Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!